⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy

Debarati Bhanja Junjia Zhu Hannah Wilding Jorge Benavides‐Vasquez Leonardo de Macêdo Filho Ahmad Ozair Camille Moeckel Aarav Badani Jinpyo Hong Jeffrey Sivik Joseph J. Drabick Colette R. Pameijer Kim Margolin Manmeet S. Ahluwalia Alireza Mansouri

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: The analysis captures the trends in melanoma brain metastasis following immunotherapy treatment.
KEY EVIDENCE: Data includes patients evaluated based on established study criteria and the resultant epidemiological patterns.
APPROACH: The work integrates analysis of population-level data with validation from a single-center for accuracy.
SIGNIFICANCE: Findings enhance understanding of melanoma brain metastasis, guiding future treatment strategies and patient management.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Real-world analysis reveals melanoma brain metastasis epidemiology in patients undergoing dual-agent immunotherapy, indicating important trends.

Abstract

Supplemental Figure 1 shows the number of patients who were included/excluded based on study criteria.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhanja et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d014a https://doi.org/10.1158/1078-0432.29760962

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 2 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy2025
2Supplemental Figure 3 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy2025
3Supplemental Table 2 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy2025
4Supplemental Table 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy2025
5Data from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy2025

Figure S1 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma2025
A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy2025
Supplementary Figure S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma2025